inv-06: Evidence summaries by intervention — summaries and inferred coverage stance by intervention
Laser therapies (HILT and LLLT): Evidence is limited and heterogeneous; HILT shows promising pain reduction in related chronic pain conditions but data specific to vulvodynia are insufficient; LLLT pilot RCT (n=34) reported improvement on one clinical measure but inconsistent effects across outcomes and requires larger trials.
Heterogeneous protocols and short follow-up limit conclusions
Ganglion impar block: Small case series (n=8) and case reports suggest short-term pain reduction with anesthetic infiltrations; CT guidance may improve accuracy in fibrotic tissue; evidence level IV and requires RCT validation.
Document imaging guidance and outcome measures when used
Transcranial direct-current stimulation: A triple-blind RCT (n=40) found no significant benefit of active stimulation over sham for intercourse pain or secondary outcomes.
Does not support routine use
Gabapentin (extended-release): A randomized, multicenter double-blind placebo-controlled cross-over trial (n=89) found gabapentin did not significantly reduce tampon test pain, intercourse pain, or daily pain versus placebo.
Findings do not support gabapentin alone as treatment for vulvodynia
Botulinum toxin (BTX-A): Observational follow-up (n=109, 79 completed) of EMG-guided levator ani injections reported reduced dyspareunia and improved QOL at 6 months in refractory localized provoked vulvodynia; randomized trials are needed.
Promising observational data but insufficient RCT evidence
Topical meloxicam + lidocaine: Early case observations reported subjective improvements but with burning/stinging side effects; evidence is preliminary and requires larger studies.
Small sample sizes; not definitive
Vaginal dilators: Small observational study (n=15) reported improved dyspareunia and sexual function scores but findings were confounded by adjunctive therapies and not widely endorsed in reviews.
Limited observational evidence
Cannabis / PEA-containing agents: Survey and cohort data show some reported pain relief; RCTs and heterogeneity of formulations limit definitive conclusions; counseling about lack of robust evidence is advised.
Heterogeneous delivery and formulations limit interpretation
Low-intensity shockwave therapy (LI-SWT): A single prospective double-blind RCT (n=32) reported clinically significant and sustained reductions in dyspareunia and improved pain threshold and sexual function up to 3 months; single-center and small sample size limit generalizability.
Promising but limited RCT evidence
Non-pharmacologic preferred options: Psychological therapy, pelvic floor physical therapy, and vestibulectomy (for selected provoked vestibulodynia) have the strongest support and should be considered foundational treatments.
Supported by multiple reviews and expert consensus